Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Correction for Stott et al., "Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis".

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02254-18. doi: 10.1128/AAC.02254-18. Print 2018 Dec. No abstract available.

2.

Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus-associated Cryptococcal Meningitis?

Beardsley J, Hoang NLT, Kibengo FM, Tung NLN, Binh TQ, Hung LQ, Chierakul W, Thwaites GE, Chau NVV, Nguyen TTT, Geskus RB, Day JN.

Clin Infect Dis. 2019 Apr 24;68(9):1494-1501. doi: 10.1093/cid/ciy725.

3.

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00885-18. doi: 10.1128/AAC.00885-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

4.

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Whalley S, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02526-17. doi: 10.1128/AAC.02526-17. Print 2018 Jul. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

5.

Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.

Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, Binh TQ, Chau NV, Farrar J, Merson L, Phuong L, Thwaites G, Van Kinh N, Thuy PT, Chierakul W, Siriboon S, Thiansukhon E, Onsanit S, Supphamongkholchaikul W, Chan AK, Heyderman R, Mwinjiwa E, van Oosterhout JJ, Imran D, Basri H, Mayxay M, Dance D, Phimmasone P, Rattanavong S, Lalloo DG, Day JN; CryptoDex Investigators.

N Engl J Med. 2016 Feb 11;374(6):542-54. doi: 10.1056/NEJMoa1509024.

6.

Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures.

Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, Haberer JE, Rooney J, Hendrix CW, Anderson PL, Huang Y, Priddy F, Gandhi M.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):13-20. doi: 10.1097/QAI.0000000000000386.

7.

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.

PLoS One. 2013 Sep 26;8(9):e74314. doi: 10.1371/journal.pone.0074314. eCollection 2013.

8.

Using verbal autopsy to assess the prevalence of HIV infection among deaths in the ART period in rural Uganda: a prospective cohort study, 2006-2008.

Mayanja BN, Baisley K, Nalweyiso N, Kibengo FM, Mugisha JO, Van der Paal L, Maher D, Kaleebu P.

Popul Health Metr. 2011 Aug 4;9:36. doi: 10.1186/1478-7954-9-36.

Supplemental Content

Loading ...
Support Center